Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On March 28, 2017, CADTH published the fourth edition of the Guidelines for Economic Evaluation of Health Technologies: Canada, which set out the best practices for determining the economic value of health technologies.
On March 28, 2017, CADTH published the fourth
edition of the Guidelines for Economic Evaluation of Health
Technologies: Canada, which set out the best practices for
determining the economic value of health technologies. The updated
guidelines account for methodological advancements that have
occurred in the economic evaluation of health technologies since
the publication of the last edition of the guidelines in 2006.
Advancements in methodology include a probabilistic analysis, which
accounts for uncertainty in source data. The guidelines were
authored by a working group of leading Canadian health economists
and created through consultation with patient and industry
groups.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
